Highly Specialised Technology Archives -

An 11-year-old girl with the rare disease phenylketonuria (PKU) has lost a legal battle in the High Court

Girl loses High Court battle over NICE review of BioMarin’s PKU drug

https://pharmaphorum.com/news/girl-loses-high-court-battle-over-nice-review-of-biomarins-pku-drug/

Project will initially focus on DMD but could benefit other rare diseases

Pharma collaborates to improve chances of NICE backing Duchenne drugs

https://pharmaphorum.com/news/pharmas-join-improve-duchenne-muscular-dystrophy/

A new way to capture when drugs are ‘cost effective’ but not ‘affordable’ looks set to be introduced in England.

Budget impact and cost effectiveness: alternatives to NICE and NHSE proposals

https://pharmaphorum.com/views-and-analysis/budget-impact-cost-effectiveness-alternatives-nice-nhse-proposals/

Leela Barham examines the process for the appraisal of Highly Specialised Technologies.

NICE and Highly Specialised Technologies: three years on

https://pharmaphorum.com/views-and-analysis/nice-and-highly-specialised-technologies-three-years-on/

With the appraisal process for highly specialised treatments in the UK described by one NHS insider as ‘impenetrable’,

Funding rare disease treatments in the UK – navigating the labyrinth

https://pharmaphorum.com/views-and-analysis/funding-rare-disease-treatments-in-the-uk-navigating-the-labyrinth/

Highly Specialised Technology